Physician profile
Jesse Bashor
NPI 1063161339
$1,264.72
in general payments reported to CMS, 2019-2025
14 companies · $927 in 2025
The $927 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $338 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $489.10 | 2024-2025 | Rezdiffra |
| Novo Nordisk INC | $326.88 | 2025 | Ozempic, Wegovy |
| Astellas Pharma US INC | $102.39 | 2024 | Veozah |
| Radius Health, INC. | $75.46 | 2024-2025 | Tymlos |
| Amgen INC. | $50.39 | 2025 | Evenity, Otezla |
| Lilly USA, LLC | $45.92 | 2025 | Zepbound, Mounjaro |
| Dexcom, INC. | $34.89 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $32.74 | 2025 | |
| Vital Connect, INC | $21.30 | 2025 | Vitalpatch Rtm |
| Eisai INC. | $20.57 | 2024 | |
| Abbott Laboratories | $19.19 | 2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $17.84 | 2025 | Gemtesa |
| Abbvie INC. | $14.40 | 2025 | |
| Esperion Therapeutics, INC. | $13.65 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Bashor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.